001     303016
005     20250819093532.0
024 7 _ |a 10.3205/000339
|2 doi
024 7 _ |a pmid:40655928
|2 pmid
024 7 _ |a pmc:PMC12247573
|2 pmc
037 _ _ |a DKFZ-2025-01463
041 _ _ |a English
082 _ _ |a 310
100 1 _ |a Dietz, Andreas
|b 0
245 _ _ |a Evidence-based guideline diagnosis, treatment, prevention and aftercare of oropharyngeal and hypopharyngeal carcinoma. = GMS Ger Med Sci
260 _ _ |a Berlin
|c 2025
|b German Medical Science (GMS) gGmbH
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1755588906_6401
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2025 Jun 24:23:Doc03
520 _ _ |a The guideline is being drawn up as a joint guideline for oropharyngeal and hypopharyngeal carcinoma. Oropharyngeal carcinoma in particular has experienced the greatest increase in incidence among all head and neck carcinomas in the last 20 years and is now the sixth most common cancer in men in Germany. Together with hypopharyngeal carcinoma, these tumors are currently the most common cancer entity in the head and neck region. Due to the association with human papillomavirus type 16 (HPV16), we now distinguish two groups of oropharyngeal carcinomas in Germany: HPV16-positive (approx. 35%) and HPV-negative (approx. 65%). A HPV16 association with hypopharyngeal carcinoma has not been described. The therapy covers the entire spectrum of head and neck surgery, including diversified reconstructive procedures, transoral and external approaches, the options for primary and adjuvant radiotherapy (possibly in combination with chemotherapy) and the current recommendations for drug-based tumor therapy, which range from classic chemotherapy to immuno-oncology. In addition, measures for early detection and prevention are carried out, with particular consideration of the HPV16-associated genesis of oropharyngeal carcinoma, as well as adequate rehabilitation after the primary treatment of oropharyngeal and hypopharyngeal carcinomas. Finally, the treatment options for recurrences or distant metastases that cannot be cured in the further course of the disease are shown and classified.
536 _ _ |a 314 - Immunologie und Krebs (POF4-314)
|0 G:(DE-HGF)POF4-314
|c POF4-314
|f POF IV
|x 0
588 _ _ |a Dataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a HPV16
|2 Other
650 _ 7 |a head and neck cancer
|2 Other
650 _ 7 |a hypopharynx carcinoma
|2 Other
650 _ 7 |a oropahyrnx carcinoma
|2 Other
650 _ 7 |a p16
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Aftercare: standards
|2 MeSH
650 _ 2 |a Combined Modality Therapy
|2 MeSH
650 _ 2 |a Evidence-Based Medicine
|2 MeSH
650 _ 2 |a Germany
|2 MeSH
650 _ 2 |a Human papillomavirus 16
|2 MeSH
650 _ 2 |a Hypopharyngeal Neoplasms: therapy
|2 MeSH
650 _ 2 |a Hypopharyngeal Neoplasms: diagnosis
|2 MeSH
650 _ 2 |a Hypopharyngeal Neoplasms: prevention & control
|2 MeSH
650 _ 2 |a Hypopharyngeal Neoplasms: virology
|2 MeSH
650 _ 2 |a Oropharyngeal Neoplasms: therapy
|2 MeSH
650 _ 2 |a Oropharyngeal Neoplasms: diagnosis
|2 MeSH
650 _ 2 |a Oropharyngeal Neoplasms: prevention & control
|2 MeSH
650 _ 2 |a Oropharyngeal Neoplasms: virology
|2 MeSH
650 _ 2 |a Papillomavirus Infections: diagnosis
|2 MeSH
650 _ 2 |a Papillomavirus Infections: therapy
|2 MeSH
700 1 _ |a Taylor, Kathy
|b 1
700 1 _ |a Bayer, Oliver
|b 2
700 1 _ |a Singer, Susanne
|b 3
700 1 _ |a Follmann, Markus
|b 4
700 1 _ |a Nothacker, Monika
|b 5
700 1 _ |a Langer, Thomas
|b 6
700 1 _ |a Klussmann, Peter
|b 7
700 1 _ |a Lang, Stephan
|b 8
700 1 _ |a Hoffmann, Thomas
|b 9
700 1 _ |a Maschmeyer, Georg
|b 10
700 1 _ |a Wiegand, Susanne
|b 11
700 1 _ |a Fuchs, Michael
|b 12
700 1 _ |a Weichert, Wilko
|b 13
700 1 _ |a Hess, Jochen
|0 P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f
|b 14
|u dkfz
700 1 _ |a Guntinas-Lichius, Orlando
|b 15
700 1 _ |a Waterboer, Tim
|0 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
|b 16
|u dkfz
700 1 _ |a Lell, Michael
|b 17
700 1 _ |a Büntzel, Jens
|b 18
700 1 _ |a Balermpas, Panagiotis
|b 19
700 1 _ |a Schmidt, Kerstin
|b 20
700 1 _ |a Steingräber, Maria
|b 21
700 1 _ |a Klautke, Gunther
|b 22
700 1 _ |a Hellmund, Herbert
|b 23
700 1 _ |a Kissinger, Gunthard
|b 24
700 1 _ |a Brossart, Peter
|b 25
700 1 _ |a Maatouk, Imad
|b 26
700 1 _ |a Lethaus, Bernd
|b 27
700 1 _ |a Raguse, Jan
|b 28
700 1 _ |a Zöphel, Klaus
|b 29
700 1 _ |a Lippach, Kristina
|b 30
700 1 _ |a Sterr, Fritz
|b 31
700 1 _ |a Christiansen, Hans
|b 32
700 1 _ |a Duncker, Christian
|b 33
700 1 _ |a Keilmann, Annerose
|b 34
700 1 _ |a Cici, Havva
|b 35
700 1 _ |a Yzer, Jutta
|b 36
700 1 _ |a Relic, Alessandro
|b 37
700 1 _ |a Paradies, Kerstin
|b 38
700 1 _ |a Budach, Wilfried
|b 39
773 _ _ |a 10.3205/000339
|g Vol. 23
|0 PERI:(DE-600)2113606-3
|p Doc03
|t GMS german medical science
|v 23
|y 2025
|x 1612-3174
909 C O |p VDB
|o oai:inrepo02.dkfz.de:303016
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)2e5f34f1c58eda4787a14c9dc139ca5f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-314
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Immunologie und Krebs
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2020-04-23T10:55:52Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2020-04-23T10:55:52Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2020-04-23T10:55:52Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2020-04-23T10:55:52Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-06
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-06
920 1 _ |0 I:(DE-He78)E220-20160331
|k E220
|l E220 Radioonkologie Radiobiologie
|x 0
920 1 _ |0 I:(DE-He78)D320-20160331
|k D320
|l Infektionen und Krebs-Epidemiologie
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E220-20160331
980 _ _ |a I:(DE-He78)D320-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21